Opioid Contracts and Random Drug Testing for People with Chronic Pain — Think Twice

Breuer B. Pappagallo M. Portenoy R. , A national Survey on Pain Management Practices in the United States, 2006 Annual Meeting of the American Pain Society , American Pain Society Website, available at <http://www.ampainsoc.org/db2/abstract/view?poster_id=3007#100> (last visited October 11, 2009).

Fishman S. M. Bandman T. B. Edwards A. Borsook D. , “The Opioid Contract in the Management of Chronic Pain,” Journal of Pain and Symptom Management 18, no. 1 (1999): 27–37, at 31.

Arnold R. M. Han P. K. Seltzer D. , “Opioid Contracts in Chronic Nonmalignant Pain Management: Objectives and Uncertainties,” American Journal of Medicine 119, no. 4 (2006): 292–6, at 293; Nafziger A. N. Bertino J. S. Jr. , “Utility and Application of Urine Drug testing in Chronic Pain Management with Opioids,” Clinincial Journal of Pain 25, no. 1 (2009): 73–9, at 73.

Reisfield G. M. Salazar E. Bertholf R. L. , “Rational Use and Interpretation of Urine Drug Testing in Chronic Opioid Therapy,” Annals of Clinical & Laboratory Science 37, no. 4 (2007): 301–14, at 301; Heit H. A. Gourlay D. L. , “Urine Drug Testing in Pain Medicine,” Journal of Pain and Symptom Management 27, no. 3 (2004): 260–7, at 261; see Nafziger , supra note 3, at 73.

Katz N. P. Sherburne S. Beach M. Rose R. J. Vielguth J. Bradley J Fanciullo G. J. , “Behavioral Monitoring and Urine Toxicology Testing in Patients Receiving Long-term Opioid Therapy,” Anesthesia & Analgesia 97, no. 4 (2003): 1097–102, at 1097; Katz N. Fanciullo G. J. , “Role of Urine Toxicology Testing in the Management of Chronic Opioid Therapy,” Clininical Journal of Pain 18, no. 4, Supplement (2002): S76–82, at S76; Gourlay D. L. Heit H. A. Almahrezi A. , “Universal Precautions in Pain Medicine: A Rational Approach to the Treatment of Chronic Pain,” Pain Medicine 6, no. 2 (2005): 107–12, at 108; see Nafziger , supra note 3, at 73.

Passik S. D. Kirsh K. L. , “The Interface between Pain and Drug Abuse and the Evolution of Strategies to Optimize Pain Management While Minimizing Drug Abuse,” Experimental and Clinical Psychopharmacology 16, no. 5 (2008): 400–4, at 404.

See Arnold , supra note 3, at 292.

See Fishman , supra note 2, at 28; Arnold , supra note 3, at 292.

Fishman S. M. Kreis P. G. , “The Opioid Contract,” Clinical Journal of Pain 18, no. 4, Supplement (2002): S70–5, at S72; see Fishman , supra note 2, at 28

See Arnold , supra note 3, at 293.

Fishman S. M. Wilsey B. Yang J. Reisfield G. M. Bandman T. B. Borsook D. , “Adherence Monitoring and Drug Surveillance in Chronic Opioid Therapy,” Journal of Pain and Symptom Management 20, no. 4 (2000): 293–307, at 297; see Arnold , supra note 3, at 294.

Garner B. A. , ed., Blacks Law Dictionary , 7th ed. (St. Paul: West Group, 1999): at 318.

Perillo J. M. , Corbin on Contracts, vol. 7 (Newark: Matthew Bender & Company, Inc., 1998): At 376, 387.

Salmon P. Young B. , “Dependence and Caring in Clinical Communication: The Relevance of Attachment and Other Theories,” Patient Education and Counseling 74, no. 3 (2009): 331–8, at 332; McCoy M. , “Autonomy, Consent, and Medical Paternalism: Legal Issues in Medical Intervention,” Journal of Alternative and Complementary Medicine 14, no. 6 (2008): 785–92, at 786.

Spanswick C. , “What Chronic Pain Looks Like to the Clinician,” in Rashiq S. Schopflocher D. Taenzer P. Jonsson E. , eds., Chronic Pain: A Health Policy Perspective (Federal Republic of Germany: WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2008): At 94–6; Dibben M. R. Morris S. E. Lean M. E. , “Situational Trust and Co-operative Partnerships Between Physicians and Their Patients: A Theoretical Explanation Transferable from Business Practice,” Quarterly Journal of Medicine 93, no. 1 (2000): 55–61, at 55; Schei E. , “Doctoring as Leadership: The Power to Heal,” Perspectives in Biology and Medicine 49, no. 3 (2006): 393–406, at 397.

Breuer B. Pappagallo M. Tai J. Y. Portenoy R. K. , “U.S. Board-Certified Pain Physician Practices: Uniformity and Census Data of their Locations,” Journal of Pain 8, no. 3 (2007): 244–50, at 248.

See Fishman , supra note 2, at 32.

American Jurisprudence, 2nd ed., vol. 17A (Danvers: Thomson West, 2004): at 343–5.

Roskos S. E. Keenum A. J. Newman L. M. Wallace L. S. , “Literacy Demands and Formatting Characteristics of Opioid Contracts in Chronic Nonmalignant Pain Management,” Journal of Pain 8, no. 10 (2007): 753–8, at 757.

Cassell E. J. Leon A. C. Kaufman S. G. , “Preliminary Evidence of Impaired Thinking in Sick Patients,” Annals of Internal Medicine 134 (2001): 1120–3, at 1120.

See American Jurisprudence, supra note 18, at 62–3.

Collen M. , “The Case for Pain Insomnia Depression Syndrome (PIDS): A Symptom Cluster in Chronic Nonmalignant Pain,” Journal of Pain and Palliative Care Pharmacotherapy 22, no. 3 (2008): 221–5, at 222–3.

Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (Arlington: American Psychiatric Association, 2000): At 377, 599.

See Fishman , supra note 2, at 27; Arnold , supra note 3, at 292; Fishman , supra note 9, S70; Fishman , supra note 11, at 297.

See Arnold , supra note 3, at 293.

Berg J. W. Appelbaum P. S. Lidz C. W. Parker L. S. , Informed Consent: Legal Theory and Clinical Practice, 2nd ed. (New York: Oxford University Press, 2001): At 53, 65–70, 95, 308.

See Fishman , supra note 2, at 31.

See Nafziger , supra note 3, at 73; Reisfield , supra note 4, at 301; Heit , supra note 4, at 260; Katz Sherburne , supra note 5, at 1097.

See Reisfield , supra note 4, at 301; Fishman , supra note 11, at 298.

See Heit , supra note 4, at 260.

See Reisfield , supra note 4, at 303; Fishman , supra note 11, at 298.

See Fishman , supra note 11, at 298.

Chou R. Fanciullo G. J. Fine P. G. Miaskowski C. Passik S. D. Portenoy R. K. , “Opioids for Chronic Noncancer Pain: Prediction and Identification of Aberrant Drug-Related Behaviors: A Review of the Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline,” Journal of Pain 10, no. 2 (2009): 131–46, at 137.

See Nafziger , supra note 3, at 74; Fishman , supra note 11, at 297.

See Nafziger , supra note 3, at 74.

See Reisfield , supra note 4, at 312.

Smith H. Fishman S. Audette J. , Opioid Therapy: Controversies and Considerations. 21st Annual Scientific Meeting of the American Pain Society, formerly at <www.medscape.com/viewarticle433604> (last visited January 23, 2009) (link no longer available, article on file with author); see Nafziger , supra note 3, at 77; Heit , supra note 4, at 262; Fishman , supra note 11, at 298.

See Nafziger , supra note 3, at 76.

See Reisfield , supra note 4, at 307; Heit , supra note 4, at 263.

See Katz Fanciullo , supra note 5, at S79.

See Nafziger , supra note 3, at 76.

See Katz Fanciullo , supra note 5, at S80.

See Heit , supra note 4, at 264.

Id., at 265.

See Katz Fanciullo , supra note 5, at S79.

See Reisfield , supra note 4, at 307.

See Heit , supra note 4, at 263.

See Fishman , supra note 11, at 299.

See Reisfield , supra note 4, at 312.

Chou R. Ballantyne J. C. Fanciullo G. J. Fine P. G. Miaskowski C. , “Research Gaps on Use of Opioids for Chronic Noncancer Pain: Findings from a Review of the Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline,” Journal of Pain 10, no. 2 (2009): 147–59, at 152; see Nafziger , supra note 3, at 78; Reisfield , supra note 4, at 312; Heit , supra note 4, at 263; Katz Fanciullo , supra note 5, at S79–81; Fishman , supra note 11, at 297–301; Chou , supra note 34, at 137; Smith , supra note 38.

See Schei , supra note 15, at 401–2.

See Katz Fanciullo , supra note 5, at S80; Smith , supra note 38.

See Heit , supra note 4, at 261.

Thom D. H. Hall M. A. Pawlson L. G. , “Measuring Patients' Trust in Physicians When Assessing Quality of Care,” Health Affairs 23, no. 4 (2004): 124–32, at 127.

Barry C. A. Bradley C. P. Britten N. Stevenson F. A. Barber N. , “Patients' Unvoiced Agendas in General Practice Consultations: Qualitative Study,” BMJ 320 (2000): 1246–50, at 1246, 1250.

Benedetti F. , “How the Doctor's Words Affect the Patient's Brain,” Evaluation & the Health Professions 25, no. 4 (2002): 369–86, at 370, 372, 382; Thomas K. B. , “General Practice Consultations: Is there any Point in Being Positive?” British Medical Journal 294 (1987): 1200–2, at 1201.

Lee Y. Y. Lin J. L. , “The Effects of Trust in Physician on Self-efficacy, Adherence and Diabetes Outcomes,” Social Science Medicine 68, no. 6 (2009): 1060–8, at 1060–1, 1066–7; Bonds D. E. Camacho F. Bell R. A. Duren-Winfield V. T. Anderson R. T. Goff D. C. , “The Association of Patient Trust and Self-Care among Patients with Diabetes Mellitus,” BMC Family Practice 5 (2004): 26; see Thom , supra note 56, at 124.

Thom D. H. Kravitz R. L. Bell R. A. Krupat E. Azari R. , “Patient Trust in the Physician: Relationship to Patient Requests,” Family Practice 19, no. 5 (2002): 476–83, at 483.

Churchill L. R. Schenck D. , “Healing Skills for Medical Practice,” Annals of Internal Medicine 149 (2008): 720–4, at 720.

Weng H. C. , “Does the Physician's Emotional Intelligence Matter? Impacts of the Physician's Emotional Intelligence on the Trust, Patient-physician Relationship, and Satisfaction,” Health Care Management Review 33, no. 4 (2008): 280–8, at 280; see Thom , supra note 56, at 125; Lee , supra note 59, at 1061.

Kaplan S. H. Greenfield S. Ware J. E. Jr. , “Assessing the Effects of Physician-Patient Interactions on the Outcomes of Chronic Disease,” Medical Care 27, no. 3, supplement (1989): S110–27, at S124; see Schei , supra note 15, at 398; Churchill , supra note 61, at 720.

Goldenbaum D. M. Christopher M. Gallagher R. M. Fishman S. Payne R. Joranson D. Edmonson D. McKee J. Thexton A. , “Physicians Charged with Opioid Analgesic-Prescribing Offenses,” Pain Medicine 9, no. 6 (2008): 737–47, at 741.

Vaczek D. , “Top 200 Prescription Drugs of 2003,” Pharmacy Times 70, no. 7 (2004): 46–54, at 47; Vaczek D. , “Top 200 Prescription Drugs of 2004,” Pharmacy Times 71, no. 5 (2005): 41–6, at 42; “Top 200 Prescription Drugs of 2005,” Pharmacy Times 72, no. 5 (2006): 26–30, at 27; Lamb E. , “Top 200 Prescription Drugs of 2006,” Pharmacy Times 73, no. 5 (2007): 34–7, at 35; Lamb E. , “Top 200 Prescription Drugs of 2007,” Pharmacy Times 74, no. 5 (2008): 20–3, at 21.

Substance Abuse and Mental Health Services Administration, Results from the 2007 National Survey on Drug Use and Health: National Findings (2008) (Office of Applied Studies, NSDUH Series H-34, DHHS Publication No. SMA 08–4343): At 17, 18.

Id., at 6, 16.

Weaver M. Schnoll S. , “Abuse Liability in Opioid Therapy for Pain Treatment in Patients with an Addiction History,” Clinical Journal of Pain 18, no. 4, supplement (2002): S61–9, at S61.

Pain & Policy Studies Group, Achieving Balance in State Pain Policy: A Progress Report Card, 4th ed. (Madison: Pain & Policy Studies Group, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, 2008): At 2, 5.

See Spanswick , supra note 15, at 94–6; Dibben , supra note 15, at 55; Schei , supra note 15, at 397.

See Breuer , supra note 16, at 244, 248

See Katz Fanciullo , supra note 5, at S80; Gourlay , supra note 5, at 109.